Research map: Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study

Back to the article

Papers in this map

  1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries · Hyuna Sung · 2021 · 114646 citations · Cited by this paper
  2. Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection · 2026 · Related
  3. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support · Paul A. Harris · 2008 · 53399 citations · Cited by this paper
  4. Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences? · 2026 · Related
  5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  6. Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study · 2025 · Related
  7. The REDCap consortium: Building an international community of software platform partners · Paul A. Harris · 2019 · 25228 citations · Cited by this paper
  8. Understanding characteristics of contemporary cancer survival for modelling the cost-effectiveness of new interventions · 2025 · Related
  9. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2007 · 20683 citations · Cited by this paper
  10. Global determinants of cervical cancer outcomes: a health systems analysis · 2026 · Related
  11. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer · Thierry Conroy · 2011 · 7933 citations · Cited by this paper
  12. Evidence-based modelling and taxonomy of hospital-based cancer care coordination nurses’ roles and boundaries: an iterative multiphase convergent mixed study · 2025 · Related
  13. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment · Andy Trotti · 2003 · 2590 citations · Cited by this paper
  14. BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials · 2026 · Related
  15. Sample-Size Formula for the Proportional-Hazards Regression Model · David Schoenfeld · 1983 · 1109 citations · Cited by this paper
  16. Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II–III non-small cell lung cancer in Sri Lanka · 2026 · Related
  17. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial · Zev A. Wainberg · 2023 · 505 citations · Cited by this paper
  18. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges · 2025 · Related
  19. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer · Federico Nichetti · 2024 · 135 citations · Cited by this paper
  20. Lost in translation: why genomic breakthroughs are not reaching patients · 2026 · Related
  21. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). · Daniel D. Von Hoff · 2013 · 118 citations · Cited by this paper
  22. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis · Sara Pusceddu · 2019 · 117 citations · Cited by this paper
  23. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). · Zev A. Wainberg · 2023 · 69 citations · Cited by this paper
  24. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience · Ehsan Ghorani · 2015 · 66 citations · Cited by this paper
  25. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis · Luca Mastrantoni · 2024 · 52 citations · Cited by this paper
  26. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma · Ayhan Ulusakarya · 2019 · 15 citations · Cited by this paper
  27. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer · Michael Jonathon Raphael · 2021 · 14 citations · Cited by this paper
  28. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis · Kwangrok Jung · 2023 · 14 citations · Cited by this paper
  29. Inflammatory markers in predicting survival in pancreatic cancer: A Systematic review and Meta-Analysis · Rinrada Worapongpaiboon · 2025 · 13 citations · Cited by this paper
  30. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer · David Wai-Meng Tai · 2025 · 12 citations · Cited by this paper
  31. NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data · Andreas Reichinger · 2025 · 5 citations · Cited by this paper
  32. Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. · Eileen Mary O'Reilly · 2023 · 4 citations · Cited by this paper
  33. Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study · Donghong Wang · 2025 · 4 citations · Cited by this paper
  34. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer · Jennifer Jane Knox · 2025 · 3 citations · Cited by this paper
  35. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design · Masafumi Ikeda · 2025 · 2 citations · Cited by this paper
  36. Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience · Marián Liberko · 2024 · 1 citation · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)